HOME >> BIOLOGY >> NEWS
New monoclonal antibody therapies offer significant survival advantage for breast cancer patients

Paris, France, Monday 31 October 2005 - Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage. These new findings were released at the 13th European Cancer Conference (ECCO) on the recommendation of the Independent Data Monitoring Committee.

The study in question, an international, multicentre, randomised, 3-arm trial is being conducted by the Breast International Group (BIG) in collaboration with the pharmaceutical company Roche AG, manufacturers of Herceptin. In total, 5,090 early breast cancer patients have been enrolled into this trial by the 478 participating institutions from Europe, Canada, South Africa, Israel, the Asia Pacific Region, Japan and Latin America. All women accrued had HER-2 positive breast cancer (either node negative or positive) and had completed at least four cycles of an acceptable (neo) adjuvant chemotherapy regimen. For women with hormone receptor positive disease, adjuvant endocrine therapy (most commonly tamoxifen) followed chemotherapy. The average age of study participants is 49 years.

The aim of this trial is to compare the effect of 1 year of Herceptin infusions, given every 3 weeks, with one year of simple observation, on survival primarily DFS but also overall survival (OS), relapse-free survival (RFS) and distant disease free survival (DDFS), as well as comparable assessment of overall and cardiac safety. The study also consists of a 2-year arm where 2 years of 3-weekly Herceptin is being compared with observation.

Results from the 1-year arm of the study, showcased at ECCO 13, show that Herceptin is associated with a significant improvement in DFS in this group of patients. The difference in Herceptin treated women was 85.8% compared to 77.4% of women on observati
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Report calls for improved monoclonal antibodies against solid tumors
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. New antibody for EGFR causes lung cancer regression
4. A key antibody, IgG, links cells capture and disposal of germs
5. Research pinpoints West Nile virus antibody binding site
6. A single sugar found responsible for an antibodys ability to treat inflammation
7. Study shows how protein raises antibody output
8. Researchers link specific antibody presence to prevention of mother-to-baby HIV transmission
9. New study shows antibody-interleukin complexes stimulate immune responses
10. High resolution snapshots detail dynamics of a cocaine antibody
11. Immune substances may help antibody-based drugs fight cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
(Date:1/25/2017)... 2017 The Elements of Enterprise Information Security ... comprised of a comprehensive set of business processes ... digital identities and providing a secured and documented ... significant number of programs opted by enterprises to ... optimizing processes and changing policies. However, there are ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
Cached News: